MedTrace Logo

Effect of Gene Polymorphism on Cognitive Function

NCT05879341 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-05-30

No results posted yet for this study

Summary

The goal of this observational study is to study the effect of gene polymorphism on cognitive improvement in response to exercise in healthy participants. The main questions it aims to answer are:

To investigate whether FNDC5/Irisin genotype polymorphism affects cognitive function and inter-individual variability in exercise response.

To explore whether the FNDC5/Irisin gene polymorphism can act alone or interact with the BDNF gene to cause inter-individual differences in cognitive function responses to exercise gain.

Participants will be asked to perform high-intensity interval training( HIIT) on a cycle ergometer. Each high-intensity training period will be 30 seconds followed by a 4-minute rest period.

The participants will also perform cognitive tests (Vistorian stroop test and Fitlight trainer test) before and after the exercise.

Conditions

  • Polymorphosis
  • Cognitive Function

Interventions

OTHER

High intensitiy interval training

The participants will perform HIIT at 85% of their heart rate reserve. There will be 8 cycles of high intensity with four minutes of rest intervals in between.

Sponsors & Collaborators

  • Ministry of Science and Technology, Taiwan

    collaborator OTHER_GOV

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    lead OTHER

Principal Investigators

  • Dean-Chuan Wang, PhD · Kaohsiung Medical University

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-10
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05879341 on ClinicalTrials.gov